News
Watch
Conferences
Events
Partners
Publications
Resources
Biomarker Consortium
Subscribe

Michael Schuster, MD

Michael Schuster, MD

Episodes

Specialty:

All

Year:

All

EP. 1: Changing Treatment Landscape in CML

June 26th 2015

EP. 2: Nilotinib and Dasatinib Versus Imatinib in CML

June 26th 2015

EP. 3: The Importance of Frequent Monitoring in CML

June 26th 2015

EP. 4: Is It Okay to Stop Therapy in CML Patients?

June 26th 2015

EP. 5: Treatment Options in the Relapsed/Refractory Setting

June 26th 2015

Trending on OncLive

FDA Accepts NDA for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer

FDA Approves Zidesamtinib in Pretreated ROS1+ NSCLC

Dr Patel on the Unmet Need in EGFR+ Transformed Small Cell Lung Cancer

Dr Galsky on Systemic Therapy Advances in Muscle-Invasive Bladder Cancer

Teclistamab Plus Talquetamab Yields Significant Survival Benefits in Earlier-Line R/R Myeloma